title: [A cross-sectional survey of coagulation factor VIII inhibitor in children with hemophilia A].
abstract: OBJECTIVE
  To study the current situation of coagulation factor VIII (FVIII) inhibitor development in children with hemophilia A (HA) through a cross-sectional survey, and to explore the risk factors of inhibitor development in order to provide evidence for further prevention and management strategies.
  
  
  METHODS
  The clinical data of outpatients with hemophilia A in Beijing Children's Hospital seen from November 2012 to May 2013 were collected, FVIII inhibitor was screened and analyzed its risk factors.
  
  
  RESULTS
  A total of 102 HA children were enrolled, 5 were mild cases, 32 were moderate, and 65 were severe cases; the median age on enrollment was 55.5 (3.0-200.0) months:19(18.6%) of patients had inhibitors and 9 (8.8%) had low-titer inhibitors, 10 (9.8%) had high-titer inhibitors. Receiving FVIII treatment for life-threatening bleeding (P = 0.03) ,OR 4.10 (95%CI:1.17-14.32) was a risk factor for inhibitor generation and patients within 20 exposure days have more chances of inhibitor development (P = 0.04) ,OR 3.32 (95%CI:1.02-10.86) . High and intense FVIII exposure within short term was the risk factor for high titer inhibitor development (P = 0.01) ,OR 5.25 (95%CI:1.45-21.92) .
  
  
  CONCLUSIONS
  Intense FVIII exposure for severe hemorrhage was the risk factor of inhibitors development especially of high titer inhibitors.
authors.affiliation: Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China.
authors.forename: Qiqi
authors.initials: Q
authors.lastname: Wei
authors.affiliation: Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China.
authors.forename: Gang
authors.initials: G
authors.lastname: Li
authors.affiliation: Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Tang
authors.affiliation: Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China.
authors.forename: Zhenping
authors.initials: Z
authors.lastname: Chen
authors.affiliation: Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China.
authors.forename: Yingzi
authors.initials: Y
authors.lastname: Zhen
authors.affiliation: Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China.
authors.forename: Xinyi
authors.initials: X
authors.lastname: Wu
authors.affiliation: Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China.
authors.forename: Ningning
authors.initials: N
authors.lastname: Zhang
authors.affiliation: Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China.
authors.forename: Jishui
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China.
authors.forename: Guoxia
authors.initials: G
authors.lastname: Yu
authors.affiliation: Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China? Email: runhuiwu@hotmail.com.
authors.forename: Runhui
authors.initials: R
authors.lastname: Wu
mesh_terms: D000293:Adolescent; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D004305:Dose-Response Relationship, Drug; D005169:Factor VIII / Q000008:administration & dosage* / Q000037:antagonists & inhibitors*; D005260:Female; D006467:Hemophilia A / Q000097:blood / Q000628:therapy*; D006801:Humans; D007223:Infant; D008297:Male; D015999:Multivariate Analysis; D012307:Risk Factors; D013997:Time Factors
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D005169:Factor VIII